Unknown

Dataset Information

0

Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations.


ABSTRACT: Tyrosine kinase inhibitors (TKIs) show variable efficacy in epidermal growth factor receptor mutation-positive (EGFR+) NSCLC patients, even in patients harbouring the same mutation. Co-alterations may predict different outcomes to TKIs. We retrospectively analysed all consecutive EGFR+ advanced NSCLC treated with first-line TKIs at our Institutions. NGS with a 22 genes clinical panel was performed on diagnostic specimens. PD-L1 expression was also evaluated. Of the 106 analysed specimens, 59 showed concomitant pathogenic mutations. No differences in OS (mOS 22.8 vs. 29.5 months; p = 0.088), PFS (mPFS 10.9 vs. 11.2 months; p = 0.415) and ORR (55.9% vs. 68.1%; p = 0.202) were observed comparing patients without and with co-alterations. Subgroup analysis by EGFR mutation type and TKIs generation (1st/2nd vs. 3rd) did not show any difference too. No correlations of PD-L1 expression levels by co-mutational status were found. Significant associations with presence of co-alterations and younger age (p = 0.018) and baseline lymph nodes metastases (p = 0.032) were observed. Patients without concomitant alterations had a significant higher risk of bone progression (26.5% vs. 3.3%, p = 0.011). Pathogenic co-alterations does not seem to predict survival nor efficacy of EGFR TKIs in previously untreated advanced NSCLC.

SUBMITTER: Bironzo P 

PROVIDER: S-EPMC8156829 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations.

Bironzo Paolo P   Reale Maria Lucia ML   Sperone Tessa T   Tabbò Fabrizio F   Caglio Andrea A   Listì Angela A   Passiglia Francesco F   Di Maio Massimo M   Righi Luisella L   Bussolino Federico F   Scagliotti Giorgio V GV   Novello Silvia S  

Cancers 20210517 10


<h4>Background</h4>Tyrosine kinase inhibitors (TKIs) show variable efficacy in epidermal growth factor receptor mutation-positive (EGFR+) NSCLC patients, even in patients harbouring the same mutation. Co-alterations may predict different outcomes to TKIs.<h4>Methods</h4>We retrospectively analysed all consecutive EGFR+ advanced NSCLC treated with first-line TKIs at our Institutions. NGS with a 22 genes clinical panel was performed on diagnostic specimens. PD-L1 expression was also evaluated.<h4>  ...[more]

Similar Datasets

| S-EPMC7478849 | biostudies-literature
| S-EPMC5355088 | biostudies-literature
| S-EPMC9253544 | biostudies-literature
| S-EPMC5363800 | biostudies-literature
| S-EPMC8790496 | biostudies-literature
| S-EPMC8235748 | biostudies-literature
| S-EPMC11907820 | biostudies-literature
| S-EPMC5341815 | biostudies-literature
| S-EPMC8551980 | biostudies-literature
| S-EPMC11555867 | biostudies-literature